Cargando…

Neil3 induced neurogenesis protects against prion disease during the clinical phase

Base excision repair (BER) is the major pathway for repair of oxidative DNA damage. Mice with genetic knockout of the BER enzyme Neil3 display compromised neurogenesis in the sub-ventricular zone of the lateral ventricle and sub-granular layer of the dentate gyrus of the hippocampus. To elucidate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Jalland, Clara M. O., Scheffler, Katja, Benestad, Sylvie L., Moldal, Torfinn, Ersdal, Cecilie, Gunnes, Gjermund, Suganthan, Rajikala, Bjørås, Magnar, Tranulis, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122945/
https://www.ncbi.nlm.nih.gov/pubmed/27886261
http://dx.doi.org/10.1038/srep37844
_version_ 1782469667225337856
author Jalland, Clara M. O.
Scheffler, Katja
Benestad, Sylvie L.
Moldal, Torfinn
Ersdal, Cecilie
Gunnes, Gjermund
Suganthan, Rajikala
Bjørås, Magnar
Tranulis, Michael A.
author_facet Jalland, Clara M. O.
Scheffler, Katja
Benestad, Sylvie L.
Moldal, Torfinn
Ersdal, Cecilie
Gunnes, Gjermund
Suganthan, Rajikala
Bjørås, Magnar
Tranulis, Michael A.
author_sort Jalland, Clara M. O.
collection PubMed
description Base excision repair (BER) is the major pathway for repair of oxidative DNA damage. Mice with genetic knockout of the BER enzyme Neil3 display compromised neurogenesis in the sub-ventricular zone of the lateral ventricle and sub-granular layer of the dentate gyrus of the hippocampus. To elucidate the impact of oxidative DNA damage-induced neurogenesis on prion disease we applied the experimental prion disease model on Neil3-deficient mice. The incubation period for the disease was similar in both wild type and Neil3(−/−) mice and the overall neuropathology appeared unaffected by Neil3 function. However, disease in the Neil3(−/−) mice was of shorter clinical duration. We observed a mildly reduced astrogliosis in the hippocampus and striatum in the Neil3-deficient mice. Brain expression levels of neuronal progenitor markers, nestin (Nestin), sex determining region Box 2 (Sox2), Class III beta-tubulin (Tuj1) decreased towards end-stage prion disease whereas doublecortin (Dcx) levels were less affected. Neuronal nuclei (NeuN), a marker for mature neurons declined during prion disease and more pronounced in the Neil3(−/−) group. Microglial activation was prominent and appeared unaffected by loss of Neil3. Our data suggest that neurogenesis induced by Neil3 repair of oxidative DNA damage protects against prion disease during the clinical phase.
format Online
Article
Text
id pubmed-5122945
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-51229452016-12-07 Neil3 induced neurogenesis protects against prion disease during the clinical phase Jalland, Clara M. O. Scheffler, Katja Benestad, Sylvie L. Moldal, Torfinn Ersdal, Cecilie Gunnes, Gjermund Suganthan, Rajikala Bjørås, Magnar Tranulis, Michael A. Sci Rep Article Base excision repair (BER) is the major pathway for repair of oxidative DNA damage. Mice with genetic knockout of the BER enzyme Neil3 display compromised neurogenesis in the sub-ventricular zone of the lateral ventricle and sub-granular layer of the dentate gyrus of the hippocampus. To elucidate the impact of oxidative DNA damage-induced neurogenesis on prion disease we applied the experimental prion disease model on Neil3-deficient mice. The incubation period for the disease was similar in both wild type and Neil3(−/−) mice and the overall neuropathology appeared unaffected by Neil3 function. However, disease in the Neil3(−/−) mice was of shorter clinical duration. We observed a mildly reduced astrogliosis in the hippocampus and striatum in the Neil3-deficient mice. Brain expression levels of neuronal progenitor markers, nestin (Nestin), sex determining region Box 2 (Sox2), Class III beta-tubulin (Tuj1) decreased towards end-stage prion disease whereas doublecortin (Dcx) levels were less affected. Neuronal nuclei (NeuN), a marker for mature neurons declined during prion disease and more pronounced in the Neil3(−/−) group. Microglial activation was prominent and appeared unaffected by loss of Neil3. Our data suggest that neurogenesis induced by Neil3 repair of oxidative DNA damage protects against prion disease during the clinical phase. Nature Publishing Group 2016-11-25 /pmc/articles/PMC5122945/ /pubmed/27886261 http://dx.doi.org/10.1038/srep37844 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Jalland, Clara M. O.
Scheffler, Katja
Benestad, Sylvie L.
Moldal, Torfinn
Ersdal, Cecilie
Gunnes, Gjermund
Suganthan, Rajikala
Bjørås, Magnar
Tranulis, Michael A.
Neil3 induced neurogenesis protects against prion disease during the clinical phase
title Neil3 induced neurogenesis protects against prion disease during the clinical phase
title_full Neil3 induced neurogenesis protects against prion disease during the clinical phase
title_fullStr Neil3 induced neurogenesis protects against prion disease during the clinical phase
title_full_unstemmed Neil3 induced neurogenesis protects against prion disease during the clinical phase
title_short Neil3 induced neurogenesis protects against prion disease during the clinical phase
title_sort neil3 induced neurogenesis protects against prion disease during the clinical phase
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122945/
https://www.ncbi.nlm.nih.gov/pubmed/27886261
http://dx.doi.org/10.1038/srep37844
work_keys_str_mv AT jallandclaramo neil3inducedneurogenesisprotectsagainstpriondiseaseduringtheclinicalphase
AT schefflerkatja neil3inducedneurogenesisprotectsagainstpriondiseaseduringtheclinicalphase
AT benestadsylviel neil3inducedneurogenesisprotectsagainstpriondiseaseduringtheclinicalphase
AT moldaltorfinn neil3inducedneurogenesisprotectsagainstpriondiseaseduringtheclinicalphase
AT ersdalcecilie neil3inducedneurogenesisprotectsagainstpriondiseaseduringtheclinicalphase
AT gunnesgjermund neil3inducedneurogenesisprotectsagainstpriondiseaseduringtheclinicalphase
AT suganthanrajikala neil3inducedneurogenesisprotectsagainstpriondiseaseduringtheclinicalphase
AT bjørasmagnar neil3inducedneurogenesisprotectsagainstpriondiseaseduringtheclinicalphase
AT tranulismichaela neil3inducedneurogenesisprotectsagainstpriondiseaseduringtheclinicalphase